ArticleJPRAS open2026
Long-term patient-reported outcomes in pediatric partial-thickness burns using Epiprotect® and Biobrane® a retrospective comparative study.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Larger pediatric partial-thickness (PT) burns are typically managed with debridement and a skin substitute. Epiprotect® has shown comparable acute surgical outcomes and lower infection rates than Biobrane®, but data on long-term outcomes remain limited. Purpose: To compare long-term patient-reported outcomes between Biobrane® and Epiprotect® in pediatric PT burns using the Brisbane Burn Scar Impact Profile (BBSIP). Methods: We included all pediatric patients (<18 years) treated with Biobrane® or Epiprotect® for PT burns at our center between February 2018 and July 2023 who completed the BBSIP survey >12 months after injury. Total BBSIP scores were analyzed using Wilcoxon rank-sum tests and a negative binomial regression, adjusting for total body surface area (TBSA) and burn depth. Results: Forty-eight patients were included (Biobrane® Conclusions: Epiprotect® was associated with improved long-term outcomes compared to Biobrane®, particularly in larger or deeper burns. These findings support its use when long-term function and well-being are prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.